Abstract: Tamoxifen in treatment of breast cancer is replaced by aromatase inhibitors (AIs) which blocks and prevent estrogens by inhibiting aromatase enzyme. Treatments in breast cancer, such as oophorectomy, gonadotropin-releasing hormone (GnRH) agonists, chemotherapy and AIs, all decrease endogenous estrogens and cause significant decrease in bone mineral density (BMD) leading to bone loss and increase the risk of fractures. There is evidence to suggest that various musculoskeletal issues (pains) may be associated with low circulating estrogen levels. The most important and efficient step in preventing AI induced fracture risk is to assess for other clinical risk factors for osteoporosis before initiating AIs. The most robust non-BMD risk factors are age and prevalent fracture. The various steps in prevention of AIs induced fracture are. 1. Healthy and active lifestyle. 2. Regular Vitamin D and Calcium supplements. 3. Vigilant Monitoring of affected areas.